Neuroone Medical Net Worth
Neuroone Medical Net Worth Breakdown | NMTC |
Neuroone Medical Net Worth Analysis
Neuroone Medical's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Neuroone Medical's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Neuroone Medical's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Neuroone Medical's net worth analysis. One common approach is to calculate Neuroone Medical's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Neuroone Medical's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Neuroone Medical's net worth. This approach calculates the present value of Neuroone Medical's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Neuroone Medical's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Neuroone Medical's net worth. This involves comparing Neuroone Medical's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Neuroone Medical's net worth relative to its peers.
Enterprise Value |
|
To determine if Neuroone Medical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Neuroone Medical's net worth research are outlined below:
| Neuroone Medical Tec generated a negative expected return over the last 90 days | |
| Neuroone Medical Tec has some characteristics of a very speculative penny stock | |
| Neuroone Medical Tec has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 1.95 M. Net Loss for the year was (11.86 M) with loss before overhead, payroll, taxes, and interest of (3.05 M). | |
| Neuroone Medical Technologies currently holds about 10.18 M in cash with (12.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Neuroone Medical Tec has a frail financial position based on the latest SEC disclosures |
Neuroone Medical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Neuroone Medical Technologies. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Neuroone Medical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know Neuroone Medical's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Neuroone Medical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Neuroone Medical Technologies backward and forwards among themselves. Neuroone Medical's institutional investor refers to the entity that pools money to purchase Neuroone Medical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Aurum Wealth Management Group Llc | 2024-09-30 | 12 K | Tower Research Capital Llc | 2024-06-30 | 11.4 K | Advisor Group Holdings, Inc. | 2024-06-30 | 1.3 K | Bank Of America Corp | 2024-06-30 | 216 | Jpmorgan Chase & Co | 2024-06-30 | 57.0 | Centerpoint Advisors, Llc | 2024-06-30 | 0.0 | Mayo Clinic | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Simplex Trading, Llc | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 919.5 K | Nantahala Capital Management, Llc | 2024-09-30 | 798.8 K |
Follow Neuroone Medical's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 20.98 M.Market Cap |
|
Project Neuroone Medical's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (150.49) | (142.97) | |
| Return On Capital Employed | 0.84 | 0.88 | |
| Return On Assets | (20.23) | (21.25) | |
| Return On Equity | 1.00 | 0.84 |
When accessing Neuroone Medical's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Neuroone Medical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Neuroone Medical's profitability and make more informed investment decisions.
Please note, the presentation of Neuroone Medical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Neuroone Medical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Neuroone Medical's management manipulating its earnings.
Evaluate Neuroone Medical's management efficiency
Neuroone Medical Tec has return on total asset (ROA) of (1.4333) % which means that it has lost $1.4333 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4913) %, meaning that it created substantial loss on money invested by shareholders. Neuroone Medical's management efficiency ratios could be used to measure how well Neuroone Medical manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Capital Employed is expected to grow to 0.88, whereas Return On Tangible Assets are projected to grow to (142.97). At present, Neuroone Medical's Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 11.5 M, whereas Non Currrent Assets Other are projected to grow to (670.7 K).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.29) | (2.17) | |
| Tangible Book Value Per Share | (2.38) | (2.26) | |
| Enterprise Value Over EBITDA | (9.44) | (9.91) | |
| Price Book Value Ratio | (5.25) | (5.51) | |
| Enterprise Value Multiple | (9.44) | (9.91) | |
| Price Fair Value | (5.25) | (5.51) | |
| Enterprise Value | 2.8 M | 2.7 M |
Understanding the operational decisions made by Neuroone Medical management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Enterprise Value Revenue 5.0103 | Revenue 3.9 M | Quarterly Revenue Growth 0.311 | Revenue Per Share 0.158 | Return On Equity (3.49) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neuroone Medical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neuroone Medical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neuroone Medical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neuroone Medical time-series forecasting models is one of many Neuroone Medical's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Neuroone Medical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Neuroone Medical Earnings per Share Projection vs Actual
Neuroone Medical Corporate Management
| Christopher CFA | Chief Officer | Profile | |
| Hijaz Haris | Vice Marketing | Profile | |
| Ronald McClurg | Chief Officer | Profile | |
| Steven Mertens | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuroone Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuroone Medical. If investors know Neuroone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuroone Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.48) | Revenue Per Share 0.158 | Quarterly Revenue Growth 0.311 | Return On Assets (1.43) | Return On Equity (3.49) |
The market value of Neuroone Medical Tec is measured differently than its book value, which is the value of Neuroone that is recorded on the company's balance sheet. Investors also form their own opinion of Neuroone Medical's value that differs from its market value or its book value, called intrinsic value, which is Neuroone Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuroone Medical's market value can be influenced by many factors that don't directly affect Neuroone Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuroone Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuroone Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuroone Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.